The use of methotrexate in children with rheumatic diseases.
Clin Exp Rheumatol
; 28(5 Suppl 61): S122-7, 2010.
Article
em En
| MEDLINE
| ID: mdl-21044445
ABSTRACT
Methotrexate (MTX) is one of the most useful drugs for the treatment of various rheumatic diseases in children, mainly juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), and localised scleroderma. MTX is considered the standard treatment of JIA, particularly of those subgroups with polyarticular course. JIA response and remission rates to MTX are the standard for comparison with other drug modifying anti-rheumatic drug (DMARD) and biologic agents in clinical trials. On the other hand, short and long-term data suggest that MTX is a safety drug in the paediatric population with rheumatic diseases. Not surprisingly, MTX is the DMARD of choice in JIA either as monotherapeutic drug or in combination with biologic agents.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
1_ASSA2030
Problema de saúde:
1_geracao_evidencia_conhecimento
Assunto principal:
Artrite Juvenil
/
Metotrexato
/
Antirreumáticos
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Child
/
Humans
Idioma:
En
Revista:
Clin Exp Rheumatol
Ano de publicação:
2010
Tipo de documento:
Article